Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT01088841
First received: March 16, 2010
Last updated: February 22, 2011
Last verified: February 2011
  Purpose

The purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of GI satiety peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gut.


Condition Intervention Phase
Appetite and General Nutritional Disorders
Hormone Replacement
Dietary Supplement: lactisole
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Functional Significance of Gut-expressed Taste Receptors in the Secretion of Glucagon-like Peptide-1 and Peptide YY

Resource links provided by NLM:


Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • Gastrointestinal peptide secretion [ Time Frame: 2 hours blood sampling ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: April 2009
Study Completion Date: March 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 75 g glucose + 150 ppm lactisole Dietary Supplement: lactisole
lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
Other Names:
  • Glucose
  • water
Active Comparator: 75 g glucose + 300 ppm lactisole Dietary Supplement: lactisole
lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
Other Names:
  • Glucose
  • water
Active Comparator: 75 g glucose + 450 ppm lactisole Dietary Supplement: lactisole
lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
Other Names:
  • Glucose
  • water
Placebo Comparator: 75 g glucose Dietary Supplement: lactisole
lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
Other Names:
  • Glucose
  • water

Detailed Description:

There is strong evidence that taste signaling mechanisms identified in the oral epithelium also operate in the gut. It is suggested that open-type enteroendocrine cells directly sense nutrient via alpha-gustducin coupled taste receptors to modulate the secretion of glucagon like peptide-1 (GLP-1) and peptide YY (PYY). Several nutrient responsive G-protein coupled receptors have been identified in the human gut, including the sweet taste responsive T1R2/T1R3 heterodimer, the amino acid/umami responsive T1R1/T1R3 as well as GPR120 for unsaturated long-chain free fatty acids.The functional significance of sweet taste receptors in glucose stimulated secretion of GLP-1 and PYY will be determined by intragastric infusion of 75 g glucose with different concentrations of lactisole (150 ppm, 300 ppm and 450 ppm)in a double blind, 4-way crossover trial including 16 healthy subjects.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects
  • BMI of 19.0-24.5
  • Age 18-40
  • stable body weight for at least 3 month

Exclusion Criteria:

  • smoking
  • substance abuse
  • regular intake of medication
  • medical or psychiatric illness
  • gastrointestinal disorders or food allergies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01088841

Locations
Switzerland
University Hospital Basel, Clinical Research Center
Basel, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Principal Investigator: Christoph Beglinger, MD Clinical Research Center, University Hospital Basel
  More Information

No publications provided

Responsible Party: Beglinger Christoph, Prof. Dr. med., Department of Gastroenterology, University Hospital Basel, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT01088841     History of Changes
Other Study ID Numbers: EKBB 69/04.01
Study First Received: March 16, 2010
Last Updated: February 22, 2011
Health Authority: Switzerland: Ethikkommission

Additional relevant MeSH terms:
Nutrition Disorders
Glucagon
Glucagon-Like Peptide 1
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Gastrointestinal Agents
Therapeutic Uses
Incretins

ClinicalTrials.gov processed this record on April 16, 2014